Dr Paul Kelly

Five Aussie startups that raised $95.45 million this week

Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.

Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily

Vaccination biotech Vaxxas raises $49 million Series D, cuts C-suite amid broader layoffs

Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.

Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily

Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology

Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.

Robotics and software funding to drive down solar costs

The renewable energy agency commits grant funding to two solar projects: forecasting software at PV Lighthouse and robot automation of solar farm construction at Built Robotics.

Also RenewEconomy·RenewEconomy·RenewEconomy

Manufacturing news briefs – stories you might have missed

Manufacturing sector roundup: Whyalla steelworks resumes production, Maggie Beer Holdings' chief executive to depart, ReNu Energy secures hydrogen funding, Defence names grant recipients, Orthocell gains Canadian approval, and AEA appoints its advisory board.

Allergies biotech startup Prota Therapeutics innoculated with $32 million in Series A1 raise

Prota Therapeutics, a Melbourne biotech, has secured $32 million in equity and debt ahead of a Phase 3 trial of its peanut allergy therapy, with Singapore's SPRIM Global Investments leading the round.

Also SmartCompany·SmartCompany·SmartCompany·Business News Australia·Forbes Australia

From zero to five billion in five years

Perth fintech PictureWealth has bought out licence holders Futuro Financial Services and Insight Investment Services from majority owner Highfield Group, with existing leaders staying on as chairman Dennis Bashford plans succession.

Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate

Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.

Also OneVentures portfolio·Brandon Capital portfolio·@AuManufacturing·SmartCompany·Techboard·@AuManufacturing

Clinical Genomics Announces Closing of $15 Million Series A Financing Round

Diagnostics company Clinical Genomics closed a $15m Series A led by Sydney VC OneVentures to commercialise its blood test for monitoring bowel cancer recurrence; OneVentures partner Dr Paul Kelly joins its board.

HATCHTECH APPOINTS TIM WAUGH AS CEO

Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.